الفهرس 
cover englishOnly 14 pages are availabe for public view
 |  | from | 225 |  |  |
| | | from | 225 | | |
Abstract
Breast cancer is the second leading cause of cancer-related death among American women after lung cancer. Breast cancer is molecularly classified based on the presence or absence of specific receptors to luminal A, luminal B, HER-2+, and TNBC. TNBC represents about 15-20% of whole breast cancer cases. Due to the absence of these receptors, TNBC has limited therapeutic options. Our study focused on the combination strategy to better tackle these issues, which has remarkable strides in improving patient outcomes and survivability. The ability of momelotinib (MMB), a JAK/STAT inhibitor, to sensitize the TNBC to apoptosis inducer (CFM-4.16) was evaluated in MDA-MB-231 and MDA-MB-468. MMB + CFM-4.16 combinations with a combination index (CI) less than or equal to 0.5, was selected for in vitro and in vivo studies. MMB was combined with CD44 directed polymeric nanoparticles (NPs) loaded with CFM-4.16, namely CD44-T-PNPs, which selectively delivered the payload to CD44 overexpressing TNBC with a significant decrease in cell viability associated with a high dose reduction index (DRI). The mechanism underlying their synergism is based on the simultaneous downregulation of P-STAT3 and the up-regulation of CARP-1, which induced ROS-dependent apoptosis leading to caspase 3/7 elevation, cell shrinkage, DNA damage, and suppressed migration. CD44-T-PNPs showed a remarkable cellular internalization, demonstrated by uptake of a rhodamine B dye in vitro and S0456 (NIR dye) in vivo. S0456 was conjugated to NPs to form CD44-T-PNPs/S0456 that simultaneously delivered CFM-4.16 and S0456 parenterally with selective tumor targeting, prolonged circulation, minimized off-target distribution. This study investigates a promising NPs platform for CD44 mediated theranostic that can be combined with JAK/STAT inhibitors to treat TNBC.